Comparison of Sirolimus and Mycophenolate Mofetil as Salvage Treatment for Acute Graft-Versus-Host Disease  by Nishihori, T. et al.
S368 Poster Session II1.04-5.58, p5 0.04) when compared with UCB, but not with BM as
cell source (p 5 0.17).
This retrospective single institutional study of 628 consecutive al-
logeneic transplantation patients revealed some novel findings. PSC
were associated with a higher incidence of aGVHD, but not
cGVHD. The combination of FK/MTXwas associated with a lower
risk of cGVHD thanCSA/MTXand will need to be investigated fur-
ther. Validation of these findings requires large cooperative prospec-
tive studies.445
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Introduction: The inflammatory cytokine tumor necrosis factor-
a (TNFa) plays a central role in the pathogenesis of acute GVHD,
but its role in chronic GVHD is less clearly defined.We recently de-
scribed an association between the recipient TNFa gene polymor-
phisms and the severity of acute GVHD in pediatric unrelated
donor BMT (Goyal et al, Biol Blood Marrow Transplant, 2010). We
now report the correlative analyses between the recipient and donor
TNFa promoter region single nucleotide gene polymorphisms
(SNP) and the risk of acute and chronic GVHD in this cohort.
Materials and Methods: Genotyping was performed on pretrans-
plant genomic DNA samples from recipient-donor pairs (n 5
180). To address the confounding effect of population stratification,
significant associations were reanalyzed in white recipient-donor
pairs.
Results: Twenty-three patients died before day+100; 78/153 (51%)
of the remaining evaluable patients developed cGVHD with exten-
sive disease in 60/76 (79%) patients. Similar to findings in recipients,
the donor TNFa variant A allele of -863C/A SNP (HR 3.67, p 5
0.01) and the variant C allele of -1031T/C SNP (HR 2.85, p 5
0.05) were also associated with grade III-IV aGvHD. The recipient
TNFa variant A allele of - 238G/A SNP was associated with grade
II-IV aGVHD (HR 2.38; p\0.01, previously reported) as well
with cGVHD (RR 1.68; P 5 0.02). Six out of 44 (14%) patients
(14%) with variant -238A allele compare to 40/99 (40%) patients
without -238A allele did not develop acute or chronic GVHD.
The rates of only acute (16%, 18%) and only chronic GVHD
(18%, 19%) were similar in those with or without recipient -238A al-
lele, respectively. However, 23/44 (52%) patients with the -238A al-
lele developed both acute and chronic GVHD compared with 22/99
(22%) without the -238A allele (RR 2.35, p\0.01, Table 1). These
associations remained significant when analyzed in white-only re-
cipient-donor pairs. No statistically significant association was de-
tected between the donorTNFa gene polymorphisms and the risk of
cGVHD.
Table 1.
Recipient No Acute Only Only BothTNF alpha
-238 G>Aor Chronic
GVHDAcute
GVHDChronic
GVHDAcute & Chronic
GVHD P-ValueAA/AG 6/14 (14%) 7/44 (16%) 8/44 (18%) 23/44 (52%) <0.01GG 40/99 (40%) 18/99 (19%) 19/99 (19%) 22/99 (22%)Conclusions: In this large cohort of pediatricmatched unrelated do-
nor transplants: 1) The recipient and donor TNFa -863A allele and
-1031C allele are associated with grade III-IV aGvHD. 2) The recip-
ient TNFa -238A allele identifies a subset of patients who develop
both acute and chronicGVHD.These findings deserve further studyin independent cohorts and may be clinically relevant in a risk-ad-
justed approach toGVHDmanagement in pediatric unrelated donor
transplants.446
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VAGE TREATMENT FOR ACUTE GRAFT-VERSUS-HOST DISEASE
Nishihori, T.1, Pidala, J.1, Kim, J.2, Tomblyn,M.1, Anasetti, C.1 1Moffitt
Cancer Center, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL
Glucocorticoid refractory acute GVHD (aGVHD) is a major
source of mortality following allogeneic HCT. Comparative studies
to evaluate the efficacy of salvage immune suppressive agents are
lacking. We retrospectively compared the efficacy of sirolimus
(SIR) and mycophenolate mofetil (MMF) as salvage aGVHD ther-
apy for glucocorticoid refractory, dependent or intolerant patients.
Of 281 consecutive patients who received allogeneic HCT from
07/2004 to 09/2009, we identified 84 patients who received tacroli-
mus/methotrexate (Tac/MTX) GVHD prophylaxis, were treated
with glucocorticoids for grades 2-4 aGVHD, were refractory (n 5
72) or dependent (n 5 12) to glucocorticoids, and received 2nd
line GVHD treatment with MMF (n5 56) or SIR (n5 28). Demo-
graphics and treatment variables were similar except for year of
transplant (earlier for MMF). Disease diagnoses included AML (n
5 27), NHL (n 5 14), MDS (n 5 12), ALL (n 5 9), CML (n 5
7), CLL (n 5 4), SAA (n 5 2), MPD (n 5 5), MM/PCL (n 5 3),
and HL (n 5 1). Conditioning regimens were busulfan/fludarabine
for 71, and other regimens for 13. Except for 1 bone marrow graft
in each group, all received peripheral blood stem cells. Graft sources
were from HLA-matched siblings (35), or 8/8 HLA-matched unre-
lated donors (49). Overall grade distribution of aGVHD at time of
salvage for MMF vs. SIR was the following: grade 1 (13 vs. 2), grade
2 (31 vs. 16), grade 3 (9 vs. 5) and grade 4 (3 vs. 5). Median steroid
dose at the time of salvage was 1 (range 0.17 – 2.28) mg/kg for
MMF group and 1 (range 0.12 – 2.0) mg/kg for SIR group. Median
time from steroid to salvage was 20 (range 1 – 208) days for MMF
and 19 (range 1 – 275) days for SIR (p 5 0.84). Complete response
(CR) rates following initiation of MMF or SIR did not significantly
differ at the following time points: 1 week (MMF 30%, SIR 21%), 4
weeks (MMF 44%, SIR 46%), and 6 weeks (MMF 60%, SIR 58%).
Overall response rates (ORR) also did not differ significantly: 1 week
(MMF 57%, SIR 42%), 4 weeks (MMF 57%, SIR 77%), and 6 weeks
(MMF 72%, SIR 75%). Flare or progression of aGVHD while on
salvage regimen was noted in 50% (MMF) and 36% (SIR) of patients
(p5 0.64). Median overall survival from the time of salvage therapy
forMMF vs. SIR did not significantly differ, 11.6 (95%CI 7.0 – 28.1)
vs. 9.7 (95% CI 5.4 – 15.9) months, log-rank p5 0.88. These retro-
spective data suggest that MMF and SIR have comparable activity in
the treatment of steroid refractory or dependent acute GVHD.447
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DUCING GVHD WHILE PRESERVING GRAFT-VERSUS-LEUKEMIA
ACTIVITY
Metheny, L.L.1, Eid, S.3, Keller, M.3, Van Devort, A.2, Lee, Z.H.4,
Wilson, D.4, Auletta, J.2, Vant Hof, W.5, Paez, C.2, Cooke, K.R.2
1Case Western Reserve University, Cleveland, OH; 2University Hospitals
of Cleveland, Cleveland, OH; 3Case Western Reserve University, Cleve-
land, OH; 4National Center for Stem Cell and Regenerative Medicine,
Cleveland, OH; 5Athersys, Inc, Cleveland, OH
Graft-versus-host disease (GVHD) limits successful outcomes fol-
lowing allogeneic BMT (allo-BMT). The pathophysiology of
GVHD involves three distinct phases which contribute to inflamma-
tory cytokine dysregulation, the generation of cellular effectors, and
target organ injury. This framework uncovers opportunities to reg-
ulate GVHD. We examined whether reported immunosuppressive
and regenerative properties of human, bone marrow-derived
multi-potent, adult progenitor cells (hMAPCs) could regulate
GVHD using established murine models. The immuno-regulatory
